NCT02579083View on ClinicalTrials.gov

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
HIVHerpes Simplex Infections
Interventions
DRUG

MB66

10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film

DRUG

Placebo Film

The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.

Trial Locations (1)

02906

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

KBio Inc
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Boston University

OTHER

collaborator

The Miriam Hospital

OTHER

lead

KBio Inc

INDUSTRY

NCT02579083 - Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV | Biotech Hunter | Biotech Hunter